List of Studies ( Metabolite:Dolichol-20)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST000004 | AN000008 | Lipidomics studies on NIDDK / NIST human plasma samples | Blood | Human | LIPID MAPS | nM | |
ST000916 | AN001493 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Plasma | Blood | Human | Fatty liver disease | LIPID MAPS | nM |
ST000917 | AN001499 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 3:Urine | Urine | Human | Fatty liver disease | LIPID MAPS | nM |
ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Adipose tissue | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Brain | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Liver | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
ST001065 | AN001742 | Lipidomics analysis for aged mice brain cortex (part-II) | Muscle | Mouse | Takeda Pharmaceutical Company Limited | Peak area | |
ST001289 | AN002142 | Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses | Macrophages | Mouse | LIPID MAPS | pmol/1E6 cells | |
ST000915 | AN001487 | Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. Part 2:Liver | Liver | Human | Fatty liver disease | LIPID MAPS | pmol/mg |
ST001288 | AN002141 | Subcellular organelle lipidomics in TLR-4-activated macrophages | Macrophages | Mouse | LIPID MAPS | pmol/mg protein | |
ST000005 | AN000012 | Timecourse on RAW 264.7 cells treated with Kdo2-Lipid A and compactin | Macrophages | Mouse | LIPID MAPS | pmol/ug DNA | |
ST002094 | AN003422 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |